In 2022, the Association for Regenerative Medicine (ARM) reported that over 2,000 clinical trials employed cell therapy, cell-based immuno-oncology, gene therapy, or tissue engineering. The cells ...
The device, which was tested in an investigator-initiated trial, works by pushing tumor cells through fluid-filled chambers and sorting them based on how well they adhere to the chamber walls. When ...
Adherent cell assays have lagged behind in automation, slowing drug discovery. Semarion’s SemaCyte® microcarrier platform streamlines these workflows by making adherent cells assay-ready, improving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback